Differential susceptibility to 9-nitrocamptothecin (9-NC)-induced apoptosis in clones derived from a human ovarian cancer cell line: possible implications in the treatment of ovarian cancer patients with 9-NC

被引:8
|
作者
Hu, XL
Balan, KV
Ramos-DeSimone, N
Wyche, JH
Han, ZY
Pantazis, P
机构
[1] Univ Miami, Dept Biol, Lab Mol Canc Biol, Coral Gables, FL 33146 USA
[2] Acad Athens, Lab Pharmacol Pharmacotechnol, Fdn Biomed Res, Athens, Greece
关键词
9-nitrocamptothecin; apoptosis; ovarian cancer;
D O I
10.1097/00001813-200307000-00007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have investigated whether variability in the apoptotic pathway may account for the differential susceptibility to apoptosis-induction by 9-nitrocamptothecin (9-NC) in cell subpopulations derived from the human ovarian cancer cell line, SKOV-3. Quantitative differences in the apoptotic fractions of cells were assessed by flow cytometry, whereas major regulatory and executing components of the apoptotic machinery were investigated by Western blot analysis using specific antibodies. The results indicate that indeed the apoptotic pathway was activated by 9-NC in some, but not all, cells of the SKOV-3 cell line, suggesting that 9-NC alone may partially be effective for treatment of patients with ovarian cancer.
引用
收藏
页码:427 / 436
页数:10
相关论文
共 25 条
  • [1] Differential susceptibility to etoposide in clones derived from a human ovarian cancer cell line
    Balan, K. V.
    Sitaras, N. M.
    Dimas, K.
    Han, Z.
    Wyche, J. H.
    Pantazis, P.
    CHEMOTHERAPY, 2006, 52 (03) : 137 - 146
  • [2] Camptothecin and 9-nitrocamptothecin (9NC) as anti-cancer, anti-HIV and cell-differentiation agents. Development of resistance, enhancement of 9NC-induced activities and combination treatments in cell and animal models
    Pantazis, P
    Han, ZY
    Balan, K
    Wang, YB
    Wyche, JH
    ANTICANCER RESEARCH, 2003, 23 (5A) : 3623 - 3638
  • [3] A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer
    Verschraegen, CF
    Gupta, F
    Loyer, E
    Kavanagh, JJ
    Kudelka, AP
    Freedman, RS
    Edwards, CL
    Harris, N
    Steger, M
    Steltz, V
    Giovanella, BC
    Stehlin, JS
    ANTI-CANCER DRUGS, 1999, 10 (04) : 375 - 383
  • [4] Relationship between systemic exposure of 9-nitrocamptothecin (9NC, Rubitecan, RFS2000) and its 9-aminocamptothecin (9AC) metabolite and response in human colon cancer xenografts.
    Zamboni, WC
    Hamburger, DR
    Jung, LL
    Jin, R
    Joseph, E
    Strychor, S
    Sun, SL
    Ramanathan, RK
    Egorin, MJ
    Eiseman, JL
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3734S - 3734S
  • [5] Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line
    Wu, GS
    Ding, ZH
    ONCOGENE, 2002, 21 (01) : 1 - 8
  • [6] Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line
    Gen Sheng Wu
    Zhenhua Ding
    Oncogene, 2002, 21 : 1 - 8
  • [7] nc886 is induced by TGF-β and suppresses the microRNA pathway in ovarian cancer (vol 9, 1166, 2018)
    Ahn, Ji-Hye
    Lee, Hyun-Sung
    Lee, Ju-Seog
    Lee, Yeon-Su
    Park, Jong-Lyul
    Kim, Seon-Young
    Hwang, Jung-Ah
    Kunkeaw, Nawapol
    Jung, Sung Yun
    Kim, Tae Jin
    Lee, Kwang-Soo
    Jeon, Sung Ho
    Lee, Inhan
    Johnson, Betty H.
    Choi, Jung-Hye
    Lee, Yong Sun
    NATURE COMMUNICATIONS, 2018, 9
  • [8] Surgical and Medical Treatment of Clear Cell Ovarian Cancer Results From the Multicenter Italian Trials in Ovarian Cancer (MITO) 9 Retrospective Study
    Magazzino, Francescapaola
    Katsaros, Dionyssios
    Ottaiano, Alessandro
    Gadducci, Angiolo
    Pisano, Carmela
    Sorio, Roberto
    Rabaiotti, Emanuela
    Scambia, Giovanni
    Cormio, Gennaro
    Scarampi, Luca
    Greggi, Stefano
    Savarese, Antonella
    Marinaccio, Marco
    Scollo, Paolo
    Pignata, Sandro
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (06) : 1063 - 1070
  • [9] Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9)
    Esposito, Francesca
    Cecere, Sabrina Chiara
    Magazzino, Francescapaola
    Katsaros, Dionyssios
    Ottaiano, Alessandro
    Gadducci, Angiolo
    Pisano, Carmela
    Scalone, Sinnona
    Rabaiotti, Emanuela
    Salutari, Vanda
    Cormio, Gennaro
    Canuto, Emilie Marion
    Greggi, Stefano
    Savarese, Antonella
    Marinaccio, Marco
    Scollo, Paolo
    Santeufemia, Davide Adriano
    Sacco, Cosimo
    Facchini, Gaetano
    Pignata, Sandro
    ONCOLOGY, 2014, 86 (5-6) : 351 - 358
  • [10] The effect of LfcinB9 on human ovarian cancer cell SK-OV-3 is mediated by inducing apoptosis
    Sheng, Minjia
    Zhao, Yanjie
    Zhang, Aichen
    Wang, Liyan
    Zhang, Guizhen
    JOURNAL OF PEPTIDE SCIENCE, 2014, 20 (10) : 803 - 810